All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

arsenic trioxide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	244	1327-53-3

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: trisenox arsenic trioxide arsenic oxide arsenious oxide arsenious trioxide white arsenic

Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in NB4 human promyelocytic leukemia cells in vitro. Arsenic trioxide also causes damage or degradation of the fusion protein promyelocytic leukemia (PML)­ retinoic acid receptor (RAR)-alpha. Molecular weight: 197.84 Formula: As2O3 CLOGP: -2.60 LIPINSKI: None HAC: 3 HDO: 0 TPSA: 43.37 ALOGS: ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
7.50	mg	P

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.76 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
S (Water solubility)	37 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2A,ACVR2B,ACVRL1,AKT1,AKT2,AKT3,ALK,AURKA,AURKB,AURKC,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FGFR1,FLT1,FLT3,FLT4,GRK2,GRK3,GSK3B,IGF1R,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K3,MAP3K7,MAP4K1,MAPK1,MAPK10,MAPK12,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK4,MELK,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM1,PIM2,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70	85
kinase-selectivity-class	ACVR2B,AXL,CDK9,DYRK1B,EIF2AK3,GRK2,GSK3B,HIPK2,MAP2K6,MAP3K14,MAPK7,MAPK8,PIK3CB,PIK3CG,PRKDC,STK33,TEK,TGFBR1,TTK,UHMK1	20
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
Nov. 14, 2019	EMA	ACCORD HEALTHCARE SLU
Sept. 25, 2000	FDA	CEPHALON

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Differentiation syndrome	760.99	13.56	133	10854	1198	90616262
Electrocardiogram QT prolonged	203.10	13.56	120	10867	72336	90545124
Febrile neutropenia	96.38	13.56	107	10880	158242	90459218
Hepatic function abnormal	87.92	13.56	60	10927	46228	90571232
Intracranial pressure increased	54.37	13.56	23	10964	6788	90610672
White blood cell count decreased	50.30	13.56	80	10907	167029	90450431
Platelet count decreased	44.59	13.56	68	10919	136901	90480559
Alanine aminotransferase increased	43.20	13.56	62	10925	118276	90499184
Idiopathic intracranial hypertension	42.16	13.56	16	10971	3565	90613895
Aspartate aminotransferase increased	42.15	13.56	57	10930	102880	90514580
Disseminated intravascular coagulation	38.71	13.56	27	10960	21511	90595949
Lower respiratory tract infection fungal	35.91	13.56	8	10979	266	90617194
Leukaemia recurrent	34.56	13.56	11	10976	1456	90616004
Neutrophil count decreased	32.98	13.56	42	10945	71490	90545970
Pericardial effusion	31.64	13.56	30	10957	36803	90580657
Leukocytosis	30.03	13.56	27	10960	30963	90586497
Haematopoietic neoplasm	29.22	13.56	5	10982	39	90617421
Myelosuppression	28.80	13.56	34	10953	53557	90563903
Acute myeloid leukaemia	28.35	13.56	22	10965	20618	90596842
Systemic lupus erythematosus	28.08	13.56	5	10982	361891	90255569
Contraindicated product administered	23.62	13.56	5	10982	320134	90297326
Bone marrow necrosis	23.55	13.56	5	10982	132	90617328
Drug intolerance	22.76	13.56	13	10974	447578	90169882
Respiratory failure	21.97	13.56	46	10941	118372	90499088
Discomfort	20.83	13.56	4	10983	274331	90343129
Pyrexia	20.77	13.56	144	10843	660341	89957119
Gamma-glutamyltransferase increased	20.26	13.56	24	10963	37928	90579532
Gambling	20.25	13.56	5	10982	261	90617199
Blood lactate dehydrogenase increased	20.16	13.56	20	10967	25912	90591548
Wound	19.90	13.56	6	10981	302974	90314486
Chromosomal deletion	18.94	13.56	4	10983	103	90617357
VIth nerve paralysis	18.17	13.56	6	10981	892	90616568
Laryngeal inflammation	17.84	13.56	4	10983	137	90617323
Long QT syndrome	17.70	13.56	9	10978	4028	90613432
General physical health deterioration	17.09	13.56	11	10976	355104	90262356
Sweat gland tumour	17.05	13.56	4	10983	168	90617292
Blast cell count increased	16.85	13.56	5	10982	524	90616936
Infusion related reaction	16.18	13.56	16	10971	416764	90200696
Ventricular extrasystoles	15.80	13.56	13	10974	13237	90604223
Therapeutic product effect decreased	15.69	13.56	7	10980	277564	90339896
Chills	15.54	13.56	43	10944	131938	90485522
Arthropathy	15.48	13.56	13	10974	366229	90251231
Oedematous pancreatitis	14.90	13.56	5	10982	780	90616680
Leukostasis syndrome	14.57	13.56	3	10984	68	90617392
Hypoxia	14.46	13.56	29	10958	72370	90545090
Swelling	14.18	13.56	18	10969	419040	90198420
Blood cholesterol increased	13.87	13.56	4	10983	208008	90409452
Hyperaesthesia	13.81	13.56	11	10976	10691	90606769
Gastrointestinal disorder	13.70	13.56	7	10980	256680	90360780
Abdominal discomfort	13.70	13.56	23	10964	477305	90140155
Pleural effusion	13.70	13.56	37	10950	111954	90505506
Induced labour	13.68	13.56	5	10982	1003	90616457

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Differentiation syndrome	695.21	17.15	136	7034	1677	42612488
Electrocardiogram QT prolonged	303.84	17.15	152	7018	47793	42566372
Idiopathic intracranial hypertension	125.94	17.15	29	7141	801	42613364
Hyperleukocytosis	105.78	17.15	32	7138	2576	42611589
Febrile neutropenia	74.65	17.15	121	7049	185582	42428583
Hepatic function abnormal	55.41	17.15	55	7115	51512	42562653
Myelosuppression	50.74	17.15	47	7123	40414	42573751
Disseminated intravascular coagulation	39.49	17.15	33	7137	24761	42589404
Acute myeloid leukaemia	38.32	17.15	31	7139	22225	42591940
Hypokalaemia	37.62	17.15	53	7117	71668	42542497
Alanine aminotransferase increased	34.58	17.15	57	7113	88349	42525816
Haematopoietic neoplasm	32.65	17.15	6	7164	51	42614114
Platelet count decreased	30.43	17.15	70	7100	138511	42475654
Bone marrow necrosis	27.56	17.15	7	7163	294	42613871
White blood cell count increased	23.15	17.15	33	7137	45054	42569111
Pericardial effusion	20.57	17.15	25	7145	29250	42584915
Periarthritis	20.56	17.15	8	7162	1372	42612793
Septic embolus	20.42	17.15	8	7162	1397	42612768
Aspartate aminotransferase increased	20.36	17.15	42	7128	77121	42537044
Extremity necrosis	19.64	17.15	9	7161	2310	42611855
Blood lactate dehydrogenase increased	19.52	17.15	23	7147	26058	42588107
Pneumonia	19.25	17.15	129	7041	422020	42192145
Testicular haemorrhage	18.80	17.15	5	7165	252	42613913
Leukaemia recurrent	18.18	17.15	8	7162	1868	42612297
Pericarditis	17.58	17.15	16	7154	13428	42600737
Jugular vein thrombosis	17.41	17.15	8	7162	2066	42612099
Drug ineffective	17.18	17.15	52	7118	630145	41984020

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Differentiation syndrome	1395.78	13.41	259	15703	2785	110570552
Electrocardiogram QT prolonged	398.81	13.41	228	15734	108732	110464605
Febrile neutropenia	169.16	13.41	218	15744	316549	110256788
Idiopathic intracranial hypertension	147.84	13.41	44	15918	3908	110569429
Hepatic function abnormal	147.71	13.41	114	15848	89181	110484156
Hyperleukocytosis	123.06	13.41	37	15925	3402	110569935
Myelodysplastic syndrome transformation	98.42	13.41	23	15939	794	110572543
Platelet count decreased	82.14	13.41	131	15831	230312	110343025
Myelosuppression	75.41	13.41	80	15882	94260	110479077
Acute myeloid leukaemia	74.92	13.41	54	15908	38056	110535281
Disseminated intravascular coagulation	73.27	13.41	55	15907	41231	110532106
White blood cell count decreased	69.17	13.41	121	15841	229269	110344068
Alanine aminotransferase increased	68.97	13.41	107	15855	183666	110389671
Haematopoietic neoplasm	62.46	13.41	11	15951	85	110573252
Aspartate aminotransferase increased	55.68	13.41	90	15872	159846	110413491
Bone marrow necrosis	51.21	13.41	12	15950	419	110572918
Leukaemia recurrent	45.13	13.41	17	15945	3114	110570223
Pericardial effusion	44.79	13.41	48	15914	57169	110516168
Leukocytosis	41.85	13.41	45	15917	53783	110519554
Blood lactate dehydrogenase increased	39.74	13.41	40	15922	44294	110529043
Neutrophil count decreased	37.98	13.41	65	15897	120876	110452461
Intracranial pressure increased	35.67	13.41	21	15941	10514	110562823
Pneumonia	35.52	13.41	232	15730	876482	109696855
Hypokalaemia	30.96	13.41	76	15886	182372	110390965
White blood cell count increased	30.34	13.41	52	15910	96790	110476547
Pyrexia	26.24	13.41	220	15742	898045	109675292
Pleural effusion	25.99	13.41	70	15892	177639	110395698
Lower respiratory tract infection fungal	25.48	13.41	8	15954	849	110572488
Central nervous system leukaemia	23.94	13.41	7	15955	584	110572753
Treatment failure	20.85	13.41	7	15955	277227	110296110
Sepsis	20.83	13.41	98	15864	327248	110246089
Blood alkaline phosphatase increased	20.80	13.41	37	15925	70898	110502439
Gamma-glutamyltransferase increased	20.63	13.41	34	15928	61275	110512062
Lower respiratory tract infection	20.38	13.41	5	15957	243101	110330236
Testicular haemorrhage	19.63	13.41	5	15957	248	110573089
Ulnar neuritis	19.63	13.41	3	15959	8	110573329
Drug intolerance	19.46	13.41	18	15944	406494	110166843
Therapeutic reaction time decreased	19.13	13.41	11	15951	5268	110568069
Long QT syndrome	18.53	13.41	12	15950	7106	110566231
Pancytopenia	18.19	13.41	69	15893	209544	110363793
Systemic lupus erythematosus	18.14	13.41	7	15955	254331	110319006
Septic embolus	17.71	13.41	8	15954	2318	110571019
Wound	17.48	13.41	6	15956	234431	110338906
Contraindicated product administered	17.43	13.41	7	15955	248260	110325077
Staphylococcal infection	17.40	13.41	34	15928	69910	110503427
Blood cholesterol increased	17.13	13.41	3	15959	184782	110388555
Bone marrow failure	16.73	13.41	30	15932	57818	110515519
Extremity necrosis	16.73	13.41	9	15953	3793	110569544
Drug abuse	16.19	13.41	3	15959	177408	110395929
Chromosomal deletion	16.15	13.41	4	15958	177	110573160
Protein total decreased	16.04	13.41	13	15949	10877	110562460
Ventricular extrasystoles	15.99	13.41	18	15944	22623	110550714
Acute promyelocytic leukaemia	15.97	13.41	7	15955	1889	110571448
Respiratory failure	14.82	13.41	66	15896	215266	110358071
Arthropathy	14.64	13.41	12	15950	287510	110285827
Hypomagnesaemia	14.60	13.41	29	15933	60341	110512996
Hyperaesthesia	14.52	13.41	14	15948	14713	110558624
Hypoxia	14.14	13.41	46	15916	129469	110443868
Infusion related reaction	13.83	13.41	21	15941	381141	110192196
Neutropenia	13.82	13.41	97	15865	374523	110198814
Laryngeal inflammation	13.69	13.41	4	15958	333	110573004
Blast cell count increased	13.64	13.41	6	15956	1631	110571706
Oedematous pancreatitis	13.59	13.41	6	15956	1648	110571689

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01XX27	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Other antineoplastic agents
MeSH PA	D000970	Antineoplastic Agents
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:233423	antifibrotic agent

Related Drugs by ATC class:

L01XX Other antineoplastic agents 33 drugs

adagrasibafliberceptaltretamineamsacrineanagrelideasparaginasebelzutifancalaspargase pegolcelecoxibdarinaparsindenileukin diftitoxeflornithine show all 33 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute promyelocytic leukemia, FAB M3	indication	110004001
Acute myelomonocytic leukemia, FAB M4	indication	110005000
Myelodysplastic syndrome	off-label use	109995007
Hyperkalemia	contraindication	14140009
Complete atrioventricular block	contraindication	27885002
Torsades de pointes	contraindication	31722008
Hypokalemia	contraindication	43339004
Chronic heart failure	contraindication	48447003
Kidney disease	contraindication	90708001	DOID:557
Prolonged QT interval	contraindication	111975006
Hypomagnesemia	contraindication	190855004
Disease of liver	contraindication	235856003	DOID:409
Pregnancy, function	contraindication	289908002
Breastfeeding (mother)	contraindication	413712001
Congenital long QT syndrome	contraindication	442917000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Thioredoxin reductase 1, cytoplasmic	Enzyme	Q16881	TRXR1_HUMAN	INHIBITOR				CHEMBL	CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	5.82		WOMBAT-PK
Somatostatin receptor type 2	GPCR		SSR2_RAT		Kd	4.60		CHEMBL

External reference:

ID	Source
D02106	KEGG_DRUG
18330	RXNORM
C0052416	UMLSCUI
CHEBI:30621	CHEBI
CHEMBL5483015	ChEMBL_ID
DB01169	DRUGBANK_ID
D000077237	MESH_DESCRIPTOR_UI
14888	PUBCHEM_CID
S7V92P67HO	UNII
15787	MMSL
40534	MMSL
71831	MMSL
d04720	MMSL
4021238	VANDF
007172	NDDF
400907001	SNOMEDCT_US
72251000	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Arsenic Trioxide	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3498	INJECTION, SOLUTION	2 mg	INTRAVENOUS	ANDA	28 sections
Arsenic Trioxide	HUMAN PRESCRIPTION DRUG LABEL	1	14789-600	INJECTION	1 mg	INTRAVENOUS	ANDA	31 sections
Arsenic Trioxide	Human Prescription Drug Label	1	23155-869	INJECTION	1 mg	INTRAVENOUS	ANDA	31 sections
Arsenic Trioxide	Human Prescription Drug Label	1	23155-869	INJECTION	1 mg	INTRAVENOUS	ANDA	31 sections
Arsenic Trioxide	Human Prescription Drug Label	1	23155-870	INJECTION	2 mg	INTRAVENOUS	ANDA	31 sections
Arsenic Trioxide	Human Prescription Drug Label	1	23155-870	INJECTION	2 mg	INTRAVENOUS	ANDA	31 sections
Arsenic Trioxide	HUMAN PRESCRIPTION DRUG LABEL	1	25021-226	INJECTION	1 mg	INTRAVENOUS	ANDA	31 sections
Arsenic Trioxide	HUMAN PRESCRIPTION DRUG LABEL	1	25021-227	INJECTION	2 mg	INTRAVENOUS	ANDA	31 sections
Sinus HP	HUMAN OTC DRUG LABEL	11	44911-0629	LIQUID	30 [hp_X]	ORAL	unapproved drug other	9 sections
Jointox BB	HUMAN OTC DRUG LABEL	17	44911-0642	LIQUID	30 [hp_C]	ORAL	unapproved drug other	9 sections
Arsenic trioxide	HUMAN PRESCRIPTION DRUG LABEL	1	49315-005	INJECTION, SOLUTION	1 mg	INTRAVENOUS	ANDA	1 sections
Arsenic trioxide	HUMAN PRESCRIPTION DRUG LABEL	1	49315-007	INJECTION, SOLUTION	2 mg	INTRAVENOUS	ANDA	1 sections
ARSENIC TRIOXIDE	HUMAN PRESCRIPTION DRUG LABEL	1	50742-438	INJECTION	1 mg	INTRAVENOUS	ANDA	24 sections
7 Heavy Metal Detox	HUMAN OTC DRUG LABEL	61	55146-007	LIQUID	12 [hp_X]	ORAL	unapproved homeopathic	9 sections
1 Detoxification	HUMAN OTC DRUG LABEL	81	55146-011	LIQUID	12 [hp_X]	ORAL	unapproved homeopathic	9 sections
ARSENIC TRIOXIDE	Human Prescription Drug Label	1	55150-366	INJECTION, SOLUTION	2 mg	INTRAVENOUS	ANDA	28 sections
Hay Fever	HUMAN OTC DRUG LABEL	55	55714-2562	LIQUID	15 [hp_X]	ORAL	unapproved homeopathic	10 sections
BronCare	HUMAN OTC DRUG LABEL	29	55714-4840	PELLET	15 [hp_X]	ORAL	unapproved homeopathic	10 sections
Homeopathic Moon drops	HUMAN OTC DRUG LABEL	9	57556-008	LOZENGE	30 [hp_X]	ORAL	unapproved drug other	6 sections
Homeopathic Moon drops	HUMAN OTC DRUG LABEL	9	57556-008	LOZENGE	30 [hp_X]	ORAL	unapproved drug other	6 sections
Arsenic Trioxide	HUMAN PRESCRIPTION DRUG LABEL	1	63323-637	INJECTION, SOLUTION	1 mg	INTRAVENOUS	ANDA	29 sections
Trisenox	HUMAN PRESCRIPTION DRUG LABEL	1	63459-601	INJECTION, SOLUTION	2 mg	INTRAVENOUS	NDA	23 sections
Emvita 6	HUMAN OTC DRUG LABEL	5	66343-018	LIQUID	18 [hp_M]	ORAL	UNAPPROVED HOMEOPATHIC	10 sections
Arsenic Trioxide	Human Prescription Drug Label	1	68083-462	INJECTION	2 mg	INTRAVENOUS	ANDA	28 sections
Arsenic Trioxide	Human Prescription Drug Label	1	68083-535	INJECTION	1 mg	INTRAVENOUS	ANDA	28 sections
Arsenic trioxide	HUMAN PRESCRIPTION DRUG LABEL	1	68382-997	INJECTION, SOLUTION	1 mg	INTRAVENOUS	ANDA	26 sections
ARSENIC TRIOXIDE	HUMAN PRESCRIPTION DRUG LABEL	1	69918-720	INJECTION, SOLUTION	1 mg	INTRAVENOUS	ANDA	26 sections
Arsenic Trioxide	HUMAN PRESCRIPTION DRUG LABEL	1	70121-1483	INJECTION, SOLUTION	1 mg	INTRAVENOUS	ANDA	27 sections
Arsenic Trioxide	HUMAN PRESCRIPTION DRUG LABEL	1	70121-1658	INJECTION, SOLUTION	2 mg	INTRAVENOUS	ANDA	27 sections
Arsenic trioxide	HUMAN PRESCRIPTION DRUG LABEL	1	70710-1610	INJECTION, SOLUTION	2 mg	INTRAVENOUS	ANDA	26 sections